WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009061298) TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/061298    International Application No.:    PCT/US2007/023468
Publication Date: 14.05.2009 International Filing Date: 07.11.2007
IPC:
A61K 31/136 (2006.01), A61K 9/00 (2006.01), A61K 9/06 (2006.01), A61K 47/32 (2006.01), A61P 17/00 (2006.01), A61P 17/10 (2006.01)
Applicants: ALLERGAN, INC. [US/US]; 2525 Dupont Drive Irvine, CA 92612 (US) (For All Designated States Except US).
GARRETT, John Steven [US/US]; (US) (For US Only)
Inventors: GARRETT, John Steven; (US)
Agent: WURST, John E.; Allergan, Inc. 2525 Dupont Drive Irvine, CA 92612 (US)
Priority Data:
Title (EN) TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS
(FR) TRAITEMENT TOPIQUE AVEC LE DAPSONE CHEZ DES PATIENTS DÉFICIENTS EN G6PD
Abstract: front page image
(EN)The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also discloses the treatment of dermatological conditions in G6PD-def icient patients with the composition, while avoiding adverse hematologic effects.
(FR)Cette invention concerne un système d'excipient pharmaceutique comprenant une composition dermatologique sous forme de gel aqueux semi-solide, caractérisé en ce que le dapsone est dissous dans le gel de façon à pouvoir traverser la couche cornée de l'épiderme, et en ce que la composition contient aussi du dapsone à l'état microparticulaire qui ne traverse pas facilement la couche cornée de l'épiderme. L'invention décrit aussi le traitement d'affections dermatologiques chez des patients déficients en G6PD avec la composition, tout en évitant les effets indésirables hématologiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)